Journal of Endocrinological Investigation

, Volume 38, Issue 12, pp 1301–1307 | Cite as

Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA)

  • A. Ciresi
  • F. Cicciò
  • M. C. Amato
  • C. GiordanoEmail author
Original Article



This study aimed at evaluating the clinical and metabolic behavior of children with isolated growth hormone (GH)-deficiency (GHD), grouped according to the new AIFA criteria for the appropriateness of use and reimbursement of GH treatment in children.


The clinical and metabolic data of 310 prepubertal children (220 M, 90 F; mean age 10.8 years) grouped, according to new AIFA note 39, into Group A (No. 181 with a peak of GH <8 µg/l), Group B (No. 103 with a peak of GH ≥8 and <10 µg/l) and Group C (No. 26 with a peak of GH >10 µg/l) were retrospectively analyzed. Group A and B, diagnosed as having GHD, were treated with GH for at least 24 months, while Group C was analyzed only at baseline.


At baseline, Group A showed higher waist circumference than B (p = 0.031) and C (p = 0.041), while no difference in metabolic parameters was found between the three groups. After 12 and 24 months of treatment, Group B showed lower height velocity (p < 0.001 and p = 0.049, respectively) than Group A. As regards the metabolic parameters, both after 12 and 24 months of treatment, in Group B we found higher fasting glucose (p < 0.001 and p = 0.020), insulin (p = 0.002 and p = 0.011), Homa-β (p = 0.020 and p = 0.015) and Homa-IR (both p = 0.001) than Group A, with concomitant lower QUICKI (both p < 0.001) and HDL cholesterol (p = 0.020 and p = 0.011), without difference in other lipid parameters. The HbA1c levels, although always within the normal range, were found higher in Group B than Group A after 12 months (p = 0.015).


According to the new AIFA criteria, the reduction of GH cut-off for GHD diagnosis can be supported by auxological and metabolic data. The real benefits from GH therapy in children with higher stimulated GH levels at diagnosis remains to be better understand.


Growth hormone deficiency Children Italian Medicines Agency (AIFA) 


Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards

Informed consent

Informed consent for the scientific use of the data was obtained from all individual participants included in the study and from their parents.


This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.


  1. 1.
    Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. (1995) Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. J Pediatr 127(6):857–867Google Scholar
  2. 2.
    American Academy of Pediatrics (1997) Considerations related to the use of recombinant human growth hormone in children. American Academy of Pediatrics Committee on Drugs and Committee on Bioethics. Pediatrics 99(1):122–129CrossRefGoogle Scholar
  3. 3.
    Saggese G, Ranke MB, Saenger P, Rosenfeld RG, Tanaka T, Chaussain JL, Savage MO (1998) Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten years after the Availability of Recombinant Human Growth Hormone Workshop held in Pisa, Italy, 27–28 March 1998. Horm Res 50(6):320–340Google Scholar
  4. 4.
    Growth Hormone Research Society (2000) Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 85:3990–3993Google Scholar
  5. 5.
    Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44(235):291PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefPubMedGoogle Scholar
  7. 7.
    Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85(7):2402–2410CrossRefPubMedGoogle Scholar
  8. 8.
    Wit JM, Bang P (2008) European perspective on treatment approaches for growth failure. Pediatr Endocrinol Rev 5(Suppl 3):862–868PubMedGoogle Scholar
  9. 9.
    Rigamonti AE, Bozzola M, Banfi G, Meazza C, Müller EE, Cella SG (2012) Growth hormone variants: a potential avenue for a better diagnostic characterization of growth hormone deficiency in children. J Endocrinol Invest 35(10):937–944PubMedGoogle Scholar
  10. 10.
    Lee HS, Hwang JS (2011) Influence of body mass index on growth hormone responses to classic provocative tests in children with short stature. Neuroendocrinology 93(4):259–264CrossRefPubMedGoogle Scholar
  11. 11.
    Di Somma C, Ciresi A, Amato MC, Savastano S, Savanelli MC, Scarano E, Colao A, Giordano C (2014) Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index. Endocrine Nov 9 (Epub ahead of print)Google Scholar
  12. 12.
    Stanley T (2012) Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes 19(1):47–52PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Loche S, Guzzetti C, Pilia S, Ibba A, Civolani P, Porcu M, Minerba L, Casini MR (2011) Effect of body mass index on the growth hormone response to clonidine stimulation testing in children with short stature. Clin Endocrinol (Oxf) 74(6):726–731CrossRefGoogle Scholar
  14. 14.
    Kriström B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Albertsson-Wikland K (2009) Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab 94(2):483–490CrossRefPubMedGoogle Scholar
  15. 15.
    Elder CJ, Barton JS, Brook CG, Preece MA, Dattani MT, Hindmarsh PC (2008) A randomised study of the effect of two doses of biosynthetic human growth hormone on final height of children with familial short stature. Horm Res 70(2):89–92CrossRefPubMedGoogle Scholar
  16. 16.
    Zucchini S, Wasniewska M, Cisternino M, Salerno M, Iughetti L, Maghnie M, Street ME, Caruso-Nicoletti M, Cianfarani S (2008) Adult height in children with short stature and idiopathic delayed puberty after different management. Eur J Pediatr 167(6):677–681CrossRefPubMedGoogle Scholar
  17. 17.
    Bang P, Bjerknes R, Dahlgren J, Dunkel L, Gustafsson J, Juul A, Kriström B, Tapanainen P, Aberg V (2011) A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm Res Paediatr 75(5):335–345CrossRefPubMedGoogle Scholar
  18. 18.
    Dattani MT, Pringle PJ, Hindmarsh PC, Brook CG (1992) What is a normal stimulated growth hormone concentration? J Endocrinol 133(3):447–450CrossRefPubMedGoogle Scholar
  19. 19.
    Hindmarsh PC, Swift PG (1995) An assessment of growth hormone provocation tests. Arch Dis Child 72(4):362–367PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Alatzoglou KS, Webb EA, Le Tissier P, Dattani MT (2014) Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. Endocr Rev 35(3):376–432CrossRefPubMedGoogle Scholar
  21. 21.
    Loche S, Bizzarri C, Maghnie M, Faedda A, Tzialla C, Autelli M, Casini MR, Cappa M (2002) Results of early reevaluation of growth hormone secretion in short children with apparent growth hormone deficiency. J Pediatr 140(4):445–449CrossRefPubMedGoogle Scholar
  22. 22.
    Tenenbaum-Rakover Y (2008) The need to revise the cut-off level for the diagnosis of GH deficiency in children. Pediatr Endocrinol Rev 5(4):880–888PubMedGoogle Scholar
  23. 23.
    Capalbo D, Esposito A, Di Mase R, Barbieri F, Parenti G, Vajro P, Pignata C, Salerno M (2012) Update on early cardiovascular and metabolic risk factors in children and adolescents affected with growth hormone deficiency. Minerva Endocrinol 37(4):379–389PubMedGoogle Scholar
  24. 24.
    Capalbo D, Mattace Raso G, Esposito A, Di Mase R, Barbieri F, Meli R, Bruzzese D, Salerno M (2013) Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study. Clin Endocrinol (Oxf) 80(6):856–862CrossRefGoogle Scholar
  25. 25.
    Ciresi A, Amato MC, Criscimanna A, Mattina A, Vetro C, Galluzzo A, D’Acquisto G, Giordano C (2007) Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol 156(3):353–360CrossRefPubMedGoogle Scholar
  26. 26.
    Ciresi A, Amato MC, Giordano C (2014) Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. J Endocrinol Invest Oct 2 (Epub ahead of print)Google Scholar
  27. 27.
    Salerno M, Esposito V, Farina V, Radetti G, Umbaldo A, Capalbo D, Spinelli L, Muzzica S, Lombardi G, Colao A (2006) Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. J Clin Endocrinol Metab 91(4):1288–1295CrossRefPubMedGoogle Scholar
  28. 28.
    Maghnie M, Strigazzi C, Tinelli C, Autelli M, Cisternino M, Loche S, Severi F (1999) Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab 84(4):1324–1328CrossRefPubMedGoogle Scholar
  29. 29.
    Zucchini S, Pirazzoli P, Baronio F, Gennari M, Bal MO, Balsamo A, Gualandi S, Cicognani A (2006) Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab 91(11):4271–4276CrossRefPubMedGoogle Scholar
  30. 30.
    Secco A, di Iorgi N, Napoli F, Calandra E, Calcagno A, Ghezzi M, Frassinetti C, Fratangeli N, Parodi S, Benassai M, Leitner Y, Gastaldi R, Lorini R, Maghnie M, Radetti G (2009) Reassessment of the growth hormone status in young adults with childhood-onset growth hormone deficiency: reappraisal of insulin tolerance testing. J Clin Endocrinol Metab 94(11):4195–4204CrossRefPubMedGoogle Scholar
  31. 31.
    Arafat AM, Möhlig M, Weickert MO, Schöfl C, Spranger J, Pfeiffer AF (2010) Improved insulin sensitivity, preserved beta cell function and improved whole-body glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: a pilot study. Diabetologia 53(7):1304–1313CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2015

Authors and Affiliations

  • A. Ciresi
    • 1
  • F. Cicciò
    • 1
  • M. C. Amato
    • 1
  • C. Giordano
    • 1
    Email author
  1. 1.Section of Cardio-Respiratory and Endocrine-Metabolic Diseases, Biomedical Department of Internal and Specialist Medicine (DIBIMIS)University of PalermoPalermoItaly

Personalised recommendations